Needham & Company Reiterates Buy Rating, $8 PT on Trevi Therapeutics (TRVI) Ahead of PRISM Trial Readout
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| (NASDAQ: TRVI) | Delayed: 14.18 +0.32 (2.31%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.86 | 52 Week High | $ | |||
| Open | $14.35 | 52 Week Low | $ | |||
| Day High | $14.53 | P/E | N/A | |||
| Day Low | $14.09 | EPS | $ | |||
| Volume | 156,541 | |||||
